Skip to Content

Feed items

Correspondent's picture

Full Issue

Thu, 09/09/2010 - 01:30 — Correspondent

View the entire issue.

Correspondent's picture

Israeli Court Victory Moves Sun Closer to Taro Merger

Thu, 09/09/2010 - 01:30 — Correspondent

Sun Pharmaceutical has cleared a major hurdle in its attempt to merge with Israeli drugmaker Taro Pharmaceutical Industries now that the Supreme Court of Israel has denied an attempt by Taro shareholders to scuttle the deal.

Correspondent's picture

BMS Expands Antiviral Pipeline With ZymoGenetics Acquisition

Thu, 09/09/2010 - 01:30 — Correspondent

Bristol-Myers Squibb (BMS) is acquiring ZymoGenetics for about $885 million, giving it ownership of a Phase II biologic to treat hepatitis C.

Correspondent's picture

Momenta’s Bid for Generic Copaxone to Go to Trial

Thu, 09/09/2010 - 01:30 — Correspondent

A patent disagreement that could lead to generics of Teva Pharmaceutical’s blockbuster multiple sclerosis (MS) treatment Copaxone is heading for trial now that a federal judge has denied a motion for summary judgment.

Correspondent's picture

Appeals Court Denies FTC, Justice Pleas to Rehear Cipro Pay-for-Delay Case

Thu, 09/09/2010 - 01:30 — Correspondent

A federal appeals court has refused to reconsider its ruling upholding the legality of a pay-for-delay deal between Bayer and Barr Laboratories over the antibiotic Cipro.

Correspondent's picture

Vertex’s Telaprevir Excels in Treatment-Experienced HCV Population

Thu, 09/09/2010 - 01:30 — Correspondent

Boosting its chances of approval, Vertex’s telaprevir showed a 65 percent viral cure rate among the hardest-to-treat hepatitis C (HCV) patients, the company announced Tuesday.

Correspondent's picture

UC San Diego To Lead New Pharmacogenomics Project

Wed, 09/08/2010 - 18:30 — Correspondent

An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder...

Correspondent's picture

Cuts To Public Spending On Research Will Jeopardise Funding For Medical Research From Private And Charitable Sources, UK

Wed, 09/08/2010 - 18:30 — Correspondent

The Academy of Medical Sciences has warned that the UK's competitive advantage in medical science is reliant on a Government commitment to maintaining a thriving publicly funded research base. Any cuts risk damaging the UK's rich landscape of medical research funders and would jeopardise the private and charitable funding leveraged by public spending...

Correspondent's picture

Court Denies Sandoz/Momenta's Summary Judgment Of Invalidity In Copaxone(R) Litigation

Wed, 09/08/2010 - 18:30 — Correspondent

Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. District Court for the Southern District of New York has denied a motion for summary judgment filed by Sandoz Inc./Momenta Pharmaceuticals, Inc., that the patents at issue are invalid for indefiniteness. The court has not yet set a trial date...

Correspondent's picture

The Benefits Of Hormone Replacement Therapy Overstated And Harms Downplayed By Ghostwritten Articles

Wed, 09/08/2010 - 17:30 — Correspondent

The first academic analysis of the 1500 documents unsealed in recent litigation against the pharmaceutical giant Wyeth (now part of Pfizer) reveals unprecedented insights into how pharmaceutical companies use ghostwriters to insert marketing messages into articles published in medical journals. Dr...



Theme by Dr. Radut.